[1]  Tucker H. Non-Steroidal Anti-androgens in the Treatment of Prostate Cancer[J]. Drugs Future, 1990, 15(3): 255-265.

[2]  Lunglmayr G. The International Casodex Study Group. Efficacy and toterab ility of Casodex in patients with advanced prostate cancer [J]. Anti-cancer Drugs, 1995, 6(4): 508-513.

[3]  Sorbera L A, Rabasseda X, Castaner J, et al. Rosiglitazone Maleate[J]. Drugs Future, 1998, 23(9):977.

[4]  Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of Clopidogrel in atherosclerotic patients[J]. Thombosis and Haemositasis, 1996, 76(6): 939-943.

[5]  Mills D C B, Puri R, Hu C J, et al. Clopidogrel inhibits the binding of A DP analogues to the receptor mediating inhibition of platelet adenylate cyclase[J]. Arterioscler Thromb, 1992, 2: 430-436.
[6]  Salvi P, Heilmann E, Nurden P, et al. Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets Clin[J]. Appl Thromb Haemost 1996, 2: 35-42.

[7]  Barrbie C Cantello, Michael A Cawthorne, Graham P Cottam, et al. [[ω(Heterocyclylamino) alkoxy] benzyl]-2,4-thiozolidinediones as Potent Antihyperglycemic Agents[J]. Med Chem, 1994, 37(23): 3 977-3 985.